Compare Wendys Co (WEN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs Zoetis Inc — how do they compare? Wendys Co trades at $7.55 (market cap $1.45B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 21× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| WEN | ZTS | |
|---|---|---|
Market Cap | $1.45B | $30.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.89 | $150.61 |
52-Week Low | $6.17 | $71.91 |
Enterprise Value | $5.18B | $37.96B |
Dividend Yield | 3.68% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's stock (WEN) trades at $7.61, down 5.23% over 24 hours, reflecting recent volatility after takeover speculation faded. The stock shows a bearish technical trend with key support at $7 and resistance at $8. Fundamentally, the company has beaten EPS estimates for three consecutive quarters but faces declining net income margins, from 7.58% in 2025 to 5.72% projected for 2026. Recent news highlights CEO Bob Wright's turnaround efforts, including a new marketing chief appointment to address quality and traffic declines.
The outlook is mixed: valuation ratios like P/E of 11.54 and P/S of 0.66 appear attractive relative to peers, but execution risks persist amid competitive pressures. Analyst consensus is cautious with 64.71% hold ratings, though the $8.13 price target implies modest upside. Key risks include sustained traffic declines and high debt levels, with debt-to-asset ratio rising to 55.68% in 2025.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
